Novel diagnostic and therapeutic approaches for autoimmune diabetes - A prime time to treat insulitis as a disease

Clinical Immunology

Volumn 156, Issue 2, 2015, Pages 109-118

  Grönholm, Juha ^a   Lenardo, Michael J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Autoantibody; Insulitis; Tolerance; Type 1 diabetes

Indexed keywords

ANTIGEN; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; INSULIN;

AUTOIMMUNE DISEASE; CHEMOLUMINESCENCE; ELECTROCHEMILUMINESCENCE ASSAY; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; META ANALYSIS (TOPIC); NONHUMAN; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE; METABOLISM;

AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN-SECRETING CELLS; LYMPHOCYTES;

EID: 84919951805     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.11.007     Document Type: Review

References (87)

1. Roep B.O., Peakman M. Diabetogenic T lymphocytes in human type 1 diabetes. Curr. Opin. Immunol. 2011, 23:746-753.
2. Campbell-Thompson M.L., Atkinson M.A., Butler A.E., Chapman N.M., Frisk G., Gianani R., Giepmans B.N., von Herrath M.G., Hyoty H., Kay T.W., Korsgren O., Morgan N.G., Powers A.C., Pugliese A., Richardson S.J., Rowe P.A., Tracy S., In't Veld P.A. The diagnosis of insulitis in human type 1 diabetes. Diabetologia 2013, 56:2541-2543.
3. In't Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets 2011, 3:131-138.
4. Willcox A., Richardson S., Bone A., Foulis A., Morgan N. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009, 155:173-181.
5. Coppieters K.T., Dotta F., Amirian N., Campbell P.D., Kay T.W.H., Atkinson M.A., Roep B.O., von Herrath M.G. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 2012, 209:51-60.
6. Skowera A., Ellis R.J., Varela-Calviño R., Arif S., Huang G.C., Van-Krinks C., Zaremba A., Rackham C., Allen J.S., Tree T.I. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 2008, 118:3390.
7. Foulis A., Farguharson M.A., Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987, 8573:1423-1427.
8. Hinman R.M., Smith M.J., Cambier J.C. B cells and type 1 diabetes. in mice and men. Immunol. Lett. 2014, 160:128-132.
9. Driver J.P., Serreze D.V., Chen Y. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin. Immunopathol. 2011, 33:67-87.
10. Mariño E., Tan B., Binge L., Mackay C.R., Grey S.T. B-cell cross-presentation of autologous antigen precipitates diabetes. Diabetes 2012, 61:2893-2905.
11. Imagawa A., Hanafusa T., Tamura S., Moriwaki M., Itoh N., Yamamoto K., Iwahashi H., Yamagata K., Waguri M., Nanmo T., Uno S., Nakajima H., Namba M., Kawata S., Miyagawa J.I., Matsuzawa Y. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 2001, 50:1269-1273.
12. Gianani R., Campbell-Thompson M., Sarkar S., Wasserfall C., Pugliese A., Solis J., Kent S., Hering B., West E., Steck A. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 2010, 53:690-698.
13. Lehuen A., Diana J., Zaccone P., Cooke A. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 2010, 10:501-513.
14. Lernmark Å., Larsson H.E. Immune therapy in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9:92-103.
15. Concannon P., Rich S.S., Nepom G.T. Genetics of type 1A diabetes. N. Engl. J. Med. 2009, 360:1646-1654.
16. Erlich H., Valdes A.M., Noble J., Carlson J.A., Varney M., Concannon P., Mychaleckyj J.C., Todd J.A., Bonella P., Fear A.L. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk analysis of the type 1 diabetes genetics consortium families. Diabetes 2008, 57:1084-1092.
17. Harjutsalo V., Sjöberg L., Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008, 371:1777-1782.
18. Borchers A.T., Uibo R., Gershwin M. The geoepidemiology of type 1 diabetes. Autoimmun. Rev. 2010, 9:A355-A365.
19. Peng H., Hagopian W. Environmental factors in the development of type 1 diabetes. Rev. Endocr. Metab. Disord. 2006, 7:149-162.
20. Eizirik D.L., Colli M.L., Ortis F. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 2009, 5:219-226.
21. Laitinen O.H., Honkanen H., Pakkanen O., Oikarinen S., Hankaniemi M.M., Huhtala H., Ruokoranta T., Lecouturier V., Andre P., Harju R., Virtanen S.M., Lehtonen J., Almond J.W., Simell T., Simell O., Ilonen J., Veijola R., Knip M., Hyoty H. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes 2014, 63:446-455.
22. Oikarinen S., Tauriainen S., Hober D., Lucas B., Vazeou A., Sioofy-Khojine A., Bozas E., Muir P., Honkanen H., Ilonen J., Knip M., Keskinen P., Saha M.T., Huhtala H., Stanway G., Bartsocas C., Ludvigsson J., Taylor K., Hyoty H., VirDiab Study Group Virus antibody survey in different European populations indicates risk association between coxsackievirus b1 and type 1 diabetes. Diabetes 2014, 63:655-662.
23. Lo B., Swafford A.D.E., Shafer-Weaver K.A., Jerome L.F., Rakhlin L., Mathern D.R., Callahan C.A., Jiang P., Davison L.J., Stevens H.E., Lucas C.L., White J., von Borstel R., Todd J.A., Lenardo M.J. Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status. J. Transl. Med. 2011, 9:203.
24. Todd J.A. Etiology of type 1 diabetes. Immunity 2010, 32:457-467.
25. Ziegler A., Rewers M., Simell O., Simell T., Lempainen J., Steck A.K., Winkler G.S., Ilonen J., Veijola R., Knip M., Bonifacio E., Eisenbarth G.S. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013, 309:2473-2479.
26. Yu L., Robles D.T., Abiru N., Kaur P., Rewers M., Kelemen K., Eisenbarth G.S. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1701-1706.
27. Yu L., Dong F., Miao D., Fouts A.R., Wenzlau J.M., Steck A.K. Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013, 36:2266-2270.
28. Siljander H., Härkönen T., Hermann R., Simell S., Hekkala A., Salonsaari R.T., Simell T., Simell O., Ilonen J., Veijola R., Knip M. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab. Res. 2009, 25:615-622.
29. Barker J.M., Barriga K.J., Yu L., Miao D., Erlich H.A., Norris J.M., Eisenbarth G.S., Rewers M. Prediction of autoantibody positivity and progression to type 1 diabetes: diabetes autoimmunity study in the young. J. Clin. Endocrinol. Metab. 2004, 89:3896-3902.
30. Parikka V., Näntö-Salonen K., Saarinen M., Simell T., Ilonen J., Hyöty H., Veijola R., Knip M., Simell O. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012, 55:1926-1936.
31. Vehik K., Fiske S.W., Logan C.A., Agardh D., Cilio C.M., Hagopian W., Simell O., Roivainen M., She J., Briese T. Methods, quality control and specimen management in an international multi-center investigation of type 1 diabetes: TEDDY. Diabetes Metab. Res. 2013, 29:2427.
32. Sosenko J.M., Skyler J.S., Palmer J.P., Krischer J.P., Yu L., Mahon J., Beam C.A., Boulware D.C., Rafkin L., Schatz D., Eisenbarth G., Type 1 Diabetes TrialNet Study Group, Diabetes Prevention Trial-Type 1 Study Group The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013, 36:2615-2620.
33. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Chase H.P., Eisenbarth G.S., Jackson R.A. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996, 45:926-933.
34. Siljander H., Veijola R., Reunanen A., Virtanen S., Åkerblom H., Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia 2007, 50:2272-2275.
35. Korhonen S., Knip M.M., Kulmala P., Savola K., Åkerblom H.K., Knip M. Autoantibodies to GAD, IA-2 and insulin in ICA-positive first-degree relatives of children with type 1 diabetes: a comparison between parents and siblings. Diabetes Metab. Res. 2002, 18:43-48.
36. Achenbach P., Warncke K., Reiter J., Naserke H.E., Williams A.J., Bingley P.J., Bonifacio E., Ziegler A. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004, 53:384-392.
37. In't Veld P., Lievens D., De Grijse J., Ling Z., Van der Auwera B., Pipeleers-Marichal M., Gorus F., Pipeleers D. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 2007, 56:2400-2404.
38. Schlosser M., Koczwara K., Kenk H., Strebelow M., Rjasanowski I., Wassmuth R., Achenbach P., Ziegler A., Bonifacio E. In insulin-autoantibody-positive children from the general population, antibody affinity identifies those at high and low risk. Diabetologia 2005, 48:1830-1832.
39. Achenbach P., Koczwara K., Knopff A., Naserke H., Ziegler A.G., Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J. Clin. Invest. 2004, 114:589-597.
40. Törn C., Mueller P., Schlosser M., Bonifacio E., Bingley P. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008, 51:846-852.
41. Schlosser M., Mueller P., Törn C., Bonifacio E., Bingley P. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010, 53:2611-2620.
42. Bingley P., Williams A.J. Islet autoantibody testing: an end to the trials and tribulations?. Diabetes 2013, 62:4009-4011.
43. Williams A.J., Bingley P.J., Bonifacio E., Palmer J.P., Gale E.A. A novel micro-assay for insulin autoantibodies. J. Autoimmun. 1997, 10:473-478.
44. Greenbaum C.J., Palmer J., Kuglin B., Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J. Clin. Endocrinol. Metab. 1992, 74:1040-1044.
45. Williams A.J., Curnock R., Reed C.R., Easton P., Rokni S., Bingley P.J. Anti-BSA antibodies are a major cause of non-specific binding in insulin autoantibody radiobinding assays. J. Immunol. Methods 2010, 362:199-203.
46. Miao D., Guyer K.M., Dong F., Jiang L., Steck A.K., Rewers M., Eisenbarth G.S., Yu L. GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 2013, 62:4174-4178.
47. Yu L., Miao D., Scrimgeour L., Johnson K., Rewers M., Eisenbarth G.S. Distinguishing persistent insulin autoantibodies with differential risk nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012, 61:179-186.
48. Rhyne P.W., Wong O.T., Zhang Y.J., Weiner R.S. Electrochemiluminescence in bioanalysis. Bioanalysis 2009, 1:919-935.
49. Rydén A.K., Wesley J.D., Coppieters K.T., Von Herrath M.G. Non-antigenic and antigenic interventions in type 1 diabetes. Hum. Vacc. Immunother. 2013, 10:838-846.
50. Stiller C., Dupre J., Gent M., Jenner M., Keown P., Laupacis A., Martell R., Rodger N., Von Graffenried B., Wolfe B. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984, 223:1362-1367.
51. Parving H., Tarnow L., Nielsen F., Rossing P., Mandrup-Poulsen T., Osterby R., Nerup J. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999, 22:478-483.
52. Carel J., Boitard C., Eisenbarth G., Bach J., Bougnères P. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J. Autoimmun. 1996, 9:739-745.
53. Harrison L.C., Colman P.G., Dean B., Baxter R., Martin F. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985, 34:1306-1308.
54. Cook J.J., Hudson I., Harrison L.C., Dean B., Colman P.G., Werther G., Warne G.L. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989, 38:779-783.
55. Böhmer K.P., Kolb H., Kuglin B., Zielasek J., Hübinger A., Lampeter E.F., Weber B., Kolb-Bachofen V., Jastram H., Bertrams J. Linear loss of insulin secretory capacity during the last six months preceding IDDM: no effect of antiedematous therapy with ketotifen. Diabetes Care 1994, 17:138-141.
56. Gale E.A. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363:925-931.
57. Lampeter E.F., Klinghammer A., Scherbaum W.A., Heinze E., Haastert B., Giani G., Kolb H. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 1998, 47:980-984.
58. Eisenbarth G.S., Srikanta S., Jackson R., Rabinowe S., Dolinar R., Aoki T., Morris M.A. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 1985, 2:271-276.
59. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
60. Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., Vandemeulebroucke E., Van de Velde U., Crenier L., De Block C. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010, 53:614-623.
61. Herold K.C., Gitelman S., Greenbaum C., Puck J., Hagopian W., Gottlieb P., Sayre P., Bianchine P., Wong E., Seyfert-Margolis V. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5years. Clin. Immunol. 2009, 132:166-173.
62. Herold K.C., Gitelman S.E., Ehlers M.R., Gottlieb P.A., Greenbaum C.J., Hagopian W., Boyle K.D., Keyes-Elstein L., Aggarwal S., Phippard D., Sayre P.H., McNamara J., Bluestone J.A., AbATE Study Team Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, 62:3766-3774.
63. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
64. Pescovitz M.D., Greenbaum C.J., Bundy B., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., Moran A., Raskin P., Rodriguez H., Schatz D.A., Wherrett D.K., Wilson D.M., Krischer J.P., Skyler J.S., The Type 1 Diabetes TrialNet Anti-CD20 Study Group B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 2013, 37:453-459.
65. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Gottlieb P.A., Greenbaum C.J., Marks J.B., Monzavi R. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
66. Moran A., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Greenbaum C.J., Herold K.C., Marks J.B., Raskin P. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013, 381:60023-60029.
67. Srikanta S., Ricker A., McCulloch D., Soeldner J., Eisenbarth G., Palmer J. Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. Diabetes 1986, 35:139-142.
68. Daniel C., Weigmann B., Bronson R., von Boehmer H. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J. Exp. Med. 2011, 208:1501-1510.
69. Karounos D., Bryson J., Cohen D. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J. Clin. Invest. 1997, 100:1344-1348.
70. Keller R., Jackson R., Eisenbarth G., Eisenbarth G. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993, 341:927-928.
71. Pugliese A., Gianani R., Moromisato R., Awdeh Z.L., Alper C.A., Erlich H.A., Jackson R.A., Eisenbarth G.S. HLA-DQB1* 0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 1995, 44:608-613.
72. Diabetes Prevention Trial-Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 2002, 346:1685-1691.
73. Zhang Z.J., Davidson L., Eisenbarth G., Weiner H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. 1991, 88:10252-10256.
74. Harrison L.C., Dempsey-Collier M., Kramer D.R., Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J. Exp. Med. 1996, 184:2167-2174.
75. Skyler J., Krischer J., Wolfsdorf J., Cowie C., Palmer J., Greenbaum C., Cuthbertson D., Rafkin-Mervis L., Chase H., Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005, 28:1068-1076.
76. Harrison L.C., Honeyman M.C., Steele C.E., Stone N.L., Sarugeri E., Bonifacio E., Couper J.J., Colman P.G. Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27:2348-2355.
77. Näntö-Salonen K., Kupila A., Simell S., Siljander H., Salonsaari T., Hekkala A., Korhonen S., Erkkola R., Sipilä J.I., Haavisto L. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372:1746-1755.
78. Critchfield J.M., Lenardo M.J. Antigen-induced programmed T cell death as a new approach to immune therapy. Clin. Immunol. Immunopathol. 1995, 75:13-19.
79. Snow A.L., Pandiyan P., Zheng L., Krummey S.M., Lenardo M.J. The power and the promise of restimulation-induced cell death in human immune diseases. Immunol. Rev. 2010, 236:68-82.
80. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., Cannella B., Raine C.S., Goverman J., Lenardo M.J. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994, 263:1139-1143.
81. Elias D., Markovits D., Reshef T., van der Zee R., Cohen I.R. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1576-1580.
82. Elias D., Reshef T., Birk O.S., van der Zee R., Walker M.D., Cohen I.R. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3088-3091.
83. Fischer B., Elias D., Bretzel R.G., Linn T. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes-an update. Expert. Opin. Biol. Ther. 2010, 10:265-272.
84. Petersen J.S., Karlsen A.E., Markholst H., Worsaae A., Dyrberg T., Michelsen B. Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes 1994, 43:1478-1484.
85. Tian J., Atkinson M.A., Clare-Salzler M., Herschenfeld A., Forsthuber T., Lehmann P.V., Kaufman D.L. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 1996, 183:1561-1567.
86. Agardh C., Lynch K., Palmer M., Link K., Lernmark Å. GAD65 vaccination: 5years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009, 52:1363-1368.
87. Ludvigsson J., Hjorth M., Chéramy M., Axelsson S., Pihl M., Forsander G., Nilsson N., Samuelsson B., Wood T., Åman J. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 2011, 54:634-640.